Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

MRI study probes hidden heart risks in HIV patients

NCT ID NCT06784154

Knowledge-focused Sponsor: University of Liverpool Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study compares fat storage around the heart and liver in people with HIV versus the general population using MRI scans. Researchers aim to understand why HIV-positive individuals have double the risk of heart attacks. The study involves 100 participants aged 40 and older with well-controlled HIV.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could point toward new ways to reduce heart attack risk in people living with HIV.
What could go wrong
This is an observational study, not a treatment trial. It may not lead directly to new therapies, and results may not apply to all populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2024

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

50 participants from HIV clinic 50 participants from general population (patients undergoing CT Coronary Angiography for investigation of chest pain)

Ages

40 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * • \>40 years * HIV-positive * Stable ART for \>6 months with two VL \<40 copies/ml based on local testing protocols * CD4 count \>200cells/mm3 for \>2 years from recruitment Inclusion Criteria (all) * Understand the study procedures, able to comply with study procedures and voluntarily agree to participate by giving informed written consent Exclusion Criteria: * Subjects unable to comply with the study protocol * History of severe renal impairment (eGFR \<30ml/min) * History of severe hepatic impairment (Child Pugh Score \>9) * Active hepatitis B or hepatitis C * Any active illness, which in the opinion of the investigator precludes participation in the study. * History of cancer * Active illicit intravenous drug use * Investigators may decide the subject cannot proceed if there are any relevant other abnormal results in screening assessments * History or current GLP-1 agonist use * For female subjects: pregnancy or breast feeding at screening. * Subjects currently taking: Atypical antipsychotics, omega 3 supplements, Telmisartan/Irbesartan, Thiazolidinediones or regular NSAID use. * Familial hypercholesterolaemia

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiometabolic syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

abdominal obesity-metabolic syndrome AIDS HIV infectious disease metabolic syndrome X

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiometabolic syndrome HIV

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Royal Liverpool University Hospital

    RECRUITING

    Liverpool, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.